Lifetime duration of depressive disorders in patients with type 2 diabetes

Mary de Groot, Kent A. Crick, Molly Long, Chandan Saha, Jay H. Shubrook

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

OBJECTIVE Depression in patients with type 2 diabetes (T2D) is associated with long-term complications, disability, and early mortality. No studies have systematically examined the length of episodes and remission in adults with major depressive disorder (MDD) and T2D. This study examined the course of depressive disorders in patients with T2D and MDD. RESEARCH DESIGN AND METHODS Participants (N = 50) enrolled in a behavioral intervention for adults with T2D and MDD were interviewed using the Structured Clinical Interview for DSM-IV-TR to assess history of depressive disorders at baseline (lifetime history), postintervention, and 3-month follow-up. Onset and remission dates were recorded for all Axis I depressive disorders from birth to final interview. RESULTS Average number of MDD episodes was 1.8 with a mean duration of 23.4 months (SD 31.9; range 0.5-231.3). Over the life course, mean exposure to MDD was 43.1 months (SD 46.5; range 0.5-231.3). Kaplan-Meier survival curve analysis indicated median episode duration decreased with subsequent episodes (14 months, first episode; 9 months, second episode; P < 0.002). In patients with multiple depressive episodes, recovery time was shorter with each subsequent episode (P = 0.002). No differences in length of episode or remission were observed based on chronology of T2D diagnosis. CONCLUSIONS The overall exposure to depression in this sample of adults with T2D represents a substantial period of time that can contribute to negativemedical and psychiatric outcomes. Recurrent episodes decrease in duration as do recovery periods, resulting in a waxing andwaning pattern. Findings fromthis study underscore the need to effectively diagnose and treat depression in patientswith T2D tominimize risk of future depressive episodes.

Original languageEnglish (US)
Pages (from-to)2174-2181
Number of pages8
JournalDiabetes Care
Volume39
Issue number12
DOIs
StatePublished - 2016

Fingerprint

Depressive Disorder
Type 2 Diabetes Mellitus
Major Depressive Disorder
Depression
Interviews
Chronology
Kaplan-Meier Estimate
Survival Analysis
Diagnostic and Statistical Manual of Mental Disorders
Psychiatry
Research Design
Parturition
Mortality

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Cite this

Lifetime duration of depressive disorders in patients with type 2 diabetes. / de Groot, Mary; Crick, Kent A.; Long, Molly; Saha, Chandan; Shubrook, Jay H.

In: Diabetes Care, Vol. 39, No. 12, 2016, p. 2174-2181.

Research output: Contribution to journalArticle

de Groot, Mary ; Crick, Kent A. ; Long, Molly ; Saha, Chandan ; Shubrook, Jay H. / Lifetime duration of depressive disorders in patients with type 2 diabetes. In: Diabetes Care. 2016 ; Vol. 39, No. 12. pp. 2174-2181.
@article{4ef65cf4d2fd4c179c3b4c878558ec77,
title = "Lifetime duration of depressive disorders in patients with type 2 diabetes",
abstract = "OBJECTIVE Depression in patients with type 2 diabetes (T2D) is associated with long-term complications, disability, and early mortality. No studies have systematically examined the length of episodes and remission in adults with major depressive disorder (MDD) and T2D. This study examined the course of depressive disorders in patients with T2D and MDD. RESEARCH DESIGN AND METHODS Participants (N = 50) enrolled in a behavioral intervention for adults with T2D and MDD were interviewed using the Structured Clinical Interview for DSM-IV-TR to assess history of depressive disorders at baseline (lifetime history), postintervention, and 3-month follow-up. Onset and remission dates were recorded for all Axis I depressive disorders from birth to final interview. RESULTS Average number of MDD episodes was 1.8 with a mean duration of 23.4 months (SD 31.9; range 0.5-231.3). Over the life course, mean exposure to MDD was 43.1 months (SD 46.5; range 0.5-231.3). Kaplan-Meier survival curve analysis indicated median episode duration decreased with subsequent episodes (14 months, first episode; 9 months, second episode; P < 0.002). In patients with multiple depressive episodes, recovery time was shorter with each subsequent episode (P = 0.002). No differences in length of episode or remission were observed based on chronology of T2D diagnosis. CONCLUSIONS The overall exposure to depression in this sample of adults with T2D represents a substantial period of time that can contribute to negativemedical and psychiatric outcomes. Recurrent episodes decrease in duration as do recovery periods, resulting in a waxing andwaning pattern. Findings fromthis study underscore the need to effectively diagnose and treat depression in patientswith T2D tominimize risk of future depressive episodes.",
author = "{de Groot}, Mary and Crick, {Kent A.} and Molly Long and Chandan Saha and Shubrook, {Jay H.}",
year = "2016",
doi = "10.2337/dc16-1145",
language = "English (US)",
volume = "39",
pages = "2174--2181",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "12",

}

TY - JOUR

T1 - Lifetime duration of depressive disorders in patients with type 2 diabetes

AU - de Groot, Mary

AU - Crick, Kent A.

AU - Long, Molly

AU - Saha, Chandan

AU - Shubrook, Jay H.

PY - 2016

Y1 - 2016

N2 - OBJECTIVE Depression in patients with type 2 diabetes (T2D) is associated with long-term complications, disability, and early mortality. No studies have systematically examined the length of episodes and remission in adults with major depressive disorder (MDD) and T2D. This study examined the course of depressive disorders in patients with T2D and MDD. RESEARCH DESIGN AND METHODS Participants (N = 50) enrolled in a behavioral intervention for adults with T2D and MDD were interviewed using the Structured Clinical Interview for DSM-IV-TR to assess history of depressive disorders at baseline (lifetime history), postintervention, and 3-month follow-up. Onset and remission dates were recorded for all Axis I depressive disorders from birth to final interview. RESULTS Average number of MDD episodes was 1.8 with a mean duration of 23.4 months (SD 31.9; range 0.5-231.3). Over the life course, mean exposure to MDD was 43.1 months (SD 46.5; range 0.5-231.3). Kaplan-Meier survival curve analysis indicated median episode duration decreased with subsequent episodes (14 months, first episode; 9 months, second episode; P < 0.002). In patients with multiple depressive episodes, recovery time was shorter with each subsequent episode (P = 0.002). No differences in length of episode or remission were observed based on chronology of T2D diagnosis. CONCLUSIONS The overall exposure to depression in this sample of adults with T2D represents a substantial period of time that can contribute to negativemedical and psychiatric outcomes. Recurrent episodes decrease in duration as do recovery periods, resulting in a waxing andwaning pattern. Findings fromthis study underscore the need to effectively diagnose and treat depression in patientswith T2D tominimize risk of future depressive episodes.

AB - OBJECTIVE Depression in patients with type 2 diabetes (T2D) is associated with long-term complications, disability, and early mortality. No studies have systematically examined the length of episodes and remission in adults with major depressive disorder (MDD) and T2D. This study examined the course of depressive disorders in patients with T2D and MDD. RESEARCH DESIGN AND METHODS Participants (N = 50) enrolled in a behavioral intervention for adults with T2D and MDD were interviewed using the Structured Clinical Interview for DSM-IV-TR to assess history of depressive disorders at baseline (lifetime history), postintervention, and 3-month follow-up. Onset and remission dates were recorded for all Axis I depressive disorders from birth to final interview. RESULTS Average number of MDD episodes was 1.8 with a mean duration of 23.4 months (SD 31.9; range 0.5-231.3). Over the life course, mean exposure to MDD was 43.1 months (SD 46.5; range 0.5-231.3). Kaplan-Meier survival curve analysis indicated median episode duration decreased with subsequent episodes (14 months, first episode; 9 months, second episode; P < 0.002). In patients with multiple depressive episodes, recovery time was shorter with each subsequent episode (P = 0.002). No differences in length of episode or remission were observed based on chronology of T2D diagnosis. CONCLUSIONS The overall exposure to depression in this sample of adults with T2D represents a substantial period of time that can contribute to negativemedical and psychiatric outcomes. Recurrent episodes decrease in duration as do recovery periods, resulting in a waxing andwaning pattern. Findings fromthis study underscore the need to effectively diagnose and treat depression in patientswith T2D tominimize risk of future depressive episodes.

UR - http://www.scopus.com/inward/record.url?scp=85006087857&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006087857&partnerID=8YFLogxK

U2 - 10.2337/dc16-1145

DO - 10.2337/dc16-1145

M3 - Article

VL - 39

SP - 2174

EP - 2181

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 12

ER -